Vioxx: The Rise and Fall of a Blockbuster Drug | Painted Clothes

Vioxx, a COX-2 inhibitor developed by Merck, was approved by the FDA in 1999 and quickly became a blockbuster drug, generating $2.5 billion in sales in 2003. However, concerns over its safety, particularly regarding increased risk of heart attacks and strokes, led to its voluntary withdrawal from the market in 2004. The scandal surrounding Vioxx's approval and marketing has been widely reported, with allegations of Merck's aggressive marketing tactics and the FDA's lax regulatory oversight. According to a study published in The Lancet, Vioxx may have caused up to 140,000 heart attacks in the US alone. The Vioxx debacle has had a lasting impact on the pharmaceutical industry, leading to increased scrutiny of drug safety and regulatory reforms. As of 2020, Merck has paid out over $4.8 billion in settlements related to Vioxx litigation. The Vioxx saga serves as a stark reminder of the importance of prioritizing patient safety and transparency in the development and marketing of pharmaceuticals.